Efficacy and Safety of Daraxonrasib (RMC-6236) in Previously Treated Metastatic RAS-Mutated Pancreatic Ductal Adenocarcinoma: A Systematic Review
The results show that daraxonrasib prolonged survival, slowed disease progression and led to tumour shrinkage more frequently than chemotherapy, whilst causing mainly mild, manageable side effects.